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R heumatoid arthritis (RA) is associated with reduced bone density due to many factors,  
including age,  menopause,  immobility,  chronic 
inflammation,  and especially,  glucocorticoid (GC) use.  
Despite the advent of biological disease-modifying anti-
rheumatic drugs for RA,  GCs are still one of the com-
mon treatment options.  However,  GCs are associated 
with several adverse effects.  Glucocorticoid-induced 
osteoporosis (GIOP),  a bone metabolism disorder,  is 
frequently associated with GC therapy,  and > 3 months 
use of these agents has been shown to lead to fragility 
fractures in 30% to 50% of patients [1].  Moreover,  the 
risk of fractures increases before bone mineral loss is 
detectable [2].  Therefore,  adequate prevention and 
treatment of GIOP is critically important for RA 
patients.
In Japan,  guidelines for the management and treat-
ment of GIOP were first published by the Japanese 
Society for Bone and Mineral Research (JSBMR) in 
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Glucocorticoid-induced osteoporosis (GIOP) is one of the side effects associated with glucocorticoid (GC) ther-
apy.  In 2014,  the Japanese Society for Bone and Mineral Research (JSBMR) provided new guidelines for the 
management and treatment of GIOP.  The aim of the present study was to clarify the prevalence of patients with 
rheumatoid arthritis (RA) requiring treatment according to the new guidelines and to identify risk factors asso-
ciated with lack of treatment in these patients.  Patients in the 2018 Akita Orthopedic group on Rheumatoid 
Arthritis (AORA) database were enrolled.  Of 2,234 patients with RA in the database,  683 (30.6%) met the 2014 
JSBMR guideline treatment criteria,  and 480 (70.3%) had been treated.  The untreated group included a larger 
number of males,  younger patients,  and patients treated in clinics rather than hospital (p< 0.001,  p= 0.015,  
and p < 0.001,  respectively).  Multivariate analyses found that male sex,  younger age,  and clinic-based RA care 
were significant risk factors associated with lack of treatment (p< 0.001,  p= 0.013,  and p< 0.001,  respectively).  
Thus,  male sex,  younger age,  and clinic-based care were identified as risk factors associated with lack of treat-
ment for RA patients requiring treatment according to the new guidelines.
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2004 [3].  These guidelines applied to patients aged 18 
years or older who were using or planning to use oral 
GCs for more than 3 months.  In this earlier version,  
measurement of lumbar bone mineral density (BMD) 
was essential for identifying patients needing treatment 
for GIOP,  particularly if the patient had no history of 
fragility fracture or developed a new fracture during 
treatment.  However,  because of the difficulty of 
obtaining BMD at some institutions,  adherence to these 
guidelines was reported to be low [4].  Therefore,  
JSBMR provided new guidelines for the management 
and treatment of GIOP in 2014 [5].  Again,  the guide-
lines applied to patients aged 18 years or older who were 
using or planning to use GCs for more than 3 months.  
The presence or absence of fragility fractures,  age,  GC 
dose,  and lumbar BMD were scored as fracture risk 
factors,  and treatment intervention was required when 
the score was 3 or more.  These guidelines can identify a 
subset of patients requiring therapeutic interventions to 
prevent and treat GIOP without the use of BMD scor-
ing.
To the best of our knowledge,  no study has reported 
the prevalence of GC-treated RA patients requiring 
GIOP treatment according to the new guidelines.  The 
aims of this study were to clarify this statistic and to 
identify risk factors associated with lack of treatment 
using the database of the Akita Orthopedic Group on 
Rheumatoid Arthritis (AORA) registry.
Materials and Methods
AORA registry. The AORA registry was estab-
lished in 2010 as a multi-institutional cohort of Japanese 
patients with RA in Akita Prefecture [6 , 7].  The registry 
is maintained by the Department of Orthopedic Surgery 
at Akita University Graduate School of Medicine and at 
29 affiliated institutions.  Data are collected once per 
year.  AORA is one of the larger-scale RA cohorts in 
Japan,  together with those of the National Database of 
Rheumatic Diseases of iR-net in Japan (NinJa) and the 
Institute of Rheumatology,  Rheumatoid Arthritis 
(IORRA) database [8 , 9].
Study participants. This was a retrospective,  
multicenter study.  In 2018 the AORA registry con-
tained 2,234 patients with RA.  All patients were diag-
nosed with RA according to the 1987 American College 
of Rheumatology (ACR) classification criteria and/or 
the 2010 ACR/European League Against Rheumatism 
(EULAR) classification criteria [10 , 11].  Patients whose 
scores for fracture risk were 3 or more based on the 
JSBMR 2014 guidelines for the management and treat-
ment of GIOP were identified.  Other patient informa-
tion collected included sex,  age,  prednisolone (PSL)-
equivalent GC dose,  disease duration of RA,  treatment 
facility (clinic or hospital),  and fracture risk score based 
on the JSBMR 2014 guidelines,  excluding the history of 
prior fragility fractures and lumbar BMD as these data 
are not collected in AORA.  Treatments for GIOP 
included medications such as bisphosphonates (BPs),  
denosumab,  activated vitamin D3,  selective estrogen 
receptor modulators (SERMs),  and teriparatide.  Patients 
with scores ≥ 3 were divided into 2 groups according to 
the presence (treated group) or absence (untreated 
group) of treatment for GIOP,  and patient characteris-
tics were compared between the 2 groups.  Risk factors 
associated with a lack of a therapeutic intervention for 
patients with scores ≥3 were examined.
This study was conducted in accordance with the 
ethical standards of the Helsinki Declaration of 1975,  as 
revised in 2013.  The Institutional Review Board for 
Clinical Research at Nakadori General Hospital 
approved this study (approval number: 254),  and 
informed consent was obtained from all individual par-
ticipants included in the study.
Statistical analyses. Comparisons between groups 
were performed using the Mann-Whitney U test.  Data 
regarding proportions were analyzed using the chi-
squared test.  Multiple logistic regression analysis was 
performed to assess associations between clinical vari-
ables and GIOP treatment.  All statistical analyses were 
performed using the Statistical Package for the 
Biosciences software (SPBS version 9.68; Akita 
University Graduate School of Medicine,  Akita,  Japan) 
[12].  Values of p < 0.05 were considered significant.
Results
There were 683 patients (30.6%) who met the treat-
ment criteria of the guidelines (138 males and 545 females).  
The mean age was 75.4± 8.6 years (range: 27-100 years),  
and 99.4% of patients were older than 50 years.  The 
median PSL-equivalent GC dose was 3 mg/day (range:  
2-5 mg/day),  and 94.8% of patients received a dose less 
than 7.5 mg/day.  The median disease duration of RA 
was 139 months (range: 65-247 months).  A total of 
185 patients were treated in clinics,  and 498 were 
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treated in hospitals.  The mean fracture risk score based 
on the 2014 guidelines was 4.4 ± 1.1 (range: 3-8) (Table 
1).  The fracture risk score was 3 in 39 patients (5.7%),  4 
in 413 patients (63.3%),  5 in 200 patients (29.2%),  6 in 
5 patients (0.7%),  and 8 in 26 patients (3.8%).  A total 
of 480 patients (70.3%) had been treated with some 
type of osteoporosis medication.  The most frequently 
used drugs were BPs (181 patients),  followed by denos-
umab (101 patients),  activated vitamin D3 (54 patients),  
SERMs (29 patients),  and teriparatide (17 patients).
The untreated group had a significantly higher per-
centage of males (p< 0.001).  Furthermore,  the mean age 
was significantly younger in the untreated group 
(p = 0.001).  Disease duration of RA was significantly 
shorter in the untreated group than in the treated group 
(p < 0.001).  In the untreated group,  a significantly 
larger number of patients received treatment in clinics 
than in hospitals (p < 0.001) (Table 2).  Univariate anal-
ysis showed that clinic-based care,  male sex,  younger 
age,  and shorter disease duration of RA were significant 
risk factors associated with lack of treatment interven-
tion (p < 0.001,  p < 0.001,  p = 0.015,  and p = 0.012,  
respectively).  Multivariate analysis also showed that 
clinic-based care,  male sex,  and younger age were sig-
nificant risk factors for lack of treatment intervention 
(p < 0.001,  p < 0.001,  and p = 0.013,  respectively) (Table 
3).
Discussion
This study investigated the prevalence of RA patients 
requiring GIOP treatment per the 2014 guidelines and 
identified risk factors associated with lack of treatment 
in those patients.  The results showed that the preva-
lence of RA patients requiring treatment according to 
the new JSBMR guidelines was 30.6%; of those,  only 
70.3% had indeed been treated with some type of osteo-
porosis medication.  Clinic-based care,  male sex,  and 
younger age were significant risk factors for lack of 
treatment.
The prevalence of osteoporosis (OP) was reported to 
be 2.7 times higher in patients with RA than in a nor-
mal control group [13].  Moreover,  it was reported that 
the prevalence of OP was 1.4 times higher in RA 
patients treated with GCs than in those not treated with 
GCs [13].  A previous study from France reported that 
only 22.6% and 27.3% of patients with RA who needed 
osteoporosis treatment were actually treated,  depend-
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Age (years), mean ± SD 75.4±8.6
Age distribution, % <50 4 (0.6)
50≦ <65 44 (6.6)
≧65 635 (92.8)
GC dose (PSL equivalent mg/day),
median (IQR)
3 (2-5)
GC dose distribution, % <5 409 (59.9)
5≦ <7.5 239 (34.9)
≧7.5 35 (5.2)




Scores in new guidelines, mean ± SD 4.4±1.1
Treatment for GIOP Present/None 480/203
RA,  rheumatoid arthritis; GIOP,  glucocorticoid-induced osteoporo-
sis; GC,  glucocorticoid; PSL,  prednisolone; SD,  standard devia-
tion; IQR,  interquartile range.
Data represent mean ± SD or median (25-75 th centiles) or number 
of patients.
Table 2　 Characteristics of RA patients with treated or untreated GIOP
Treated Untreated P-value
Number 480 203
Male,  % 56 (11.7) 82 (40.4) 0.001
Age (years),  mean ± SD 76.1±8.4 73.8±8.8 0.001
GC dose (PSL equivalent mg/day),  median (IQR) 3 (2.5-5) 3 (2-5) 0.171
Disease duration (months),  median (IQR) 151 (76.5-247) 111 (31-223) 0.001
Clinic,  % 109 (22.7) 76 (37.4) 0.001
RA,  rheumatoid arthritis; GIOP,  glucocorticoid-induced osteoporosis; GC,  glucocorticoid; PSL,  prednisolone; SD,  standard deviation;  
IQR,  interquartile range.
Data represent mean ± SD or median (25-75 th centiles) or number of patients.
ing on whether they applied the 2014 or 2003 GIOP 
guidelines [14].  Moreover,  compliance with the 2010 
Canadian osteoporosis treatment guidelines was low in 
patients with RA [15].  In Japan,  a previous study showed 
that the compliance rate with the JSBMR 2004 guide-
lines for GIOP was 23.3%,  and that awareness of the 
management of GIOP was lacking in both physicians 
and patients [4].  That study also reported that male sex,  
younger age,  and low-dose GC therapy were shown to 
reduce the compliance rate with the guidelines [4].  In 
the present study,  70.3% of patients had been treated 
with some type of anti-osteoporotic medication,  and 
male sex and younger age were identified as risk factors 
associated with lack of treatment of GIOP.  The mean 
age of the patients with RA in the AORA registry is 
greater than that of the patients with RA in other regis-
tries,  such as NinJa and IORRA [8 , 9].  Some studies 
have shown that the factors associated with osteoporosis 
treatment in patients with RA were older age and post-
menopausal status [16].  Therefore,  one of the reasons 
for the higher treatment rate in the present study com-
pared to previous reports may have been the inclusion 
of a larger number of older patients being treated for 
primary osteoporosis.  While postmenopausal women 
have a higher likelihood of being treated for primary 
osteoporosis,  male patients are less likely to receive 
treatment,  likely due to the low recognition of male 
osteoporosis [17].  Meanwhile,  GCs are used in many 
diseases for both men and women,  including autoim-
mune disorders,  pulmonary diseases,  and gastrointes-
tinal diseases.  GIOP is characterized by an increased 
risk of fractures regardless of sex and age.  Therefore,  
recognizing the need for therapeutic intervention for 
male and younger patients will be essential to increasing 
the treatment rate for patients with GIOP.
The present study also showed that patients who 
visited clinics instead of hospitals were less likely to be 
treated for GIOP.  Kirigaya et al.  reported that factors 
such as the inability of clinics to perform clinical tests,  
especially BMD measurements,  may explain the lower 
rate of GIOP treatment in these facilities [4].  However,  
the new guidelines do not require lumbar vertebral 
BMD measurements to identify patients who need oste-
oporosis treatment.  Therefore,  physicians need to be 
aware that BMD measurement is not an absolute 
requirement under the new guidelines.
In GIOP,  OP progresses rapidly from the start of GC 
administration and is dose-related,  and the risk of frac-
ture increases before BMD shows a decline [18].  In the 
present study,  the median PSL-equivalent dose of GC 
was 3 mg/day (range: 2-5 mg/day),  which was associ-
ated with a score of 0 points for fracture risk based on 
the new guidelines.  However,  the period of GC admin-
istration is also an important factor associated with 
fracture risk.  EULAR recommendations state that 
short-term GCs should be considered when physicians 
initiate or change conventional synthetic disease-modi-
fying antirheumatic drugs,  and GCs should be tapered 
as soon as clinically feasible because of the many risks 
associated with these agents [19].  Balasubramanian et 
al.  reported that patients who discontinued GCs for 
about 2 to 6 months had about a 30% reduction in frac-
ture risk compared to patients on continuous GCs [20].  
Therefore,  attempts to decrease the GC dose and 
shorten the period of GC administration are also con-
sidered important to prevent the occurrence of various 
side effects caused by GCs.
To the best of our knowledge,  this is the first report 
after publication of the new guidelines in 2014 to clarify 
the prevalence of GC-treated RA patients requiring 
treatment and to identify the risk factors associated with 
lack of treatment in those patients.  Despite the advent 
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Table 3　 Univariate and multivariate analysis of factors associated with lack of therapeutic intervention for GIOP in RA patients
Variables Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value
Clinic 2.037 1.427-2.906 0.001 2.481 1.685-3.655 0.001
Male 5.131 3.456-7.619 0.001 5.437 3.601-8.210 0.001
Age 0.969 0.951-0.988 0.015 0.967 0.947-0.987 0.013
Disease duration (months) 0.998 0.997-1.000 0.012 0.999 0.997-1.000 0.078
GC dose (PSL equivalent mg/day) 0.935 0.857-1.021 0.133
OR,  odds ratio; 95% CI,  95% confidence interval.
GIOP,  glucocorticoid-induced osteoporosis; GC,  glucocorticoid; PSL,  prednisolone.
of new guidelines,  the factors related to lack of treat-
ment remained the same.
Several limitations of this study should be acknowl-
edged.  First,  the presence or absence of fragility frac-
tures and lumbar BMD could not be investigated in all 
patients.  Therefore,  some patients with GIOP may not 
have been included in this study.  Second,  the 2014 
guidelines apply to patients aged 18 years or older who 
were using or planning to use GCs for more than 3 
months; unfortunately,  the duration of GC use among 
patients could not be investigated.  Therefore,  it is pos-
sible that the number of patients who met the treatment 
criteria for GIOP was overestimated.  Third,  this was a 
cross-sectional study; longitudinal studies are needed 
to determine whether treatment for GIOP should be 
initiated and whether fractures can be prevented.  
Fourth,  disease activity indices,  such as the 28-joint 
count Disease Activity Score and Steinbrocker’s Stage,  
which may be related to the risk of osteoporosis,  could 
not be investigated.  Fifth,  data on comorbidities related 
to GIOP such as diabetes mellitus,  chronic kidney dis-
ease,  chronic obstructive pulmonary disease,  hyperuri-
cemia,  hyperlipidemia,  smoking,  and drinking were 
not collected.
In conclusion,  the present study demonstrated that 
the prevalence of RA patients in the AORA registry 
requiring osteoporosis treatment per the 2014 guide-
lines was 30.6%; of these,  70.3% were treated.  Male 
sex,  younger age,  and clinic- as opposed to hospi-
tal-based care were identified as risk factors associated 
with lack of treatment in patients with RA.  Physicians 
should take care to ensure such patients are treated 
appropriately.
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